Renal disease secondary to diabetes.

Tartalom

  • Budapest Nephrology School — Program
  • Mazi kezelésére trofikus fekélyek cukorbetegség

Search Menu Abstract Background. Remikiren is an orally active renin inhibitor with established antihypertensive efficacy. As a single dose it induces renal vasodilatation, suggesting specific renal actions.

Data on the renal effects of continued treatment by renin inhibition are not available, either in subjects with normal, or in subjects with impaired renal function. The effect of 8 days renal disease secondary to diabetes treatment with remikiren mg o.

renal disease secondary to diabetes

Remikiren induced a significant peak fall in renal disease secondary to diabetes arterial pressure of Continued treatment with remikiren induced a sustained fall in blood pressure, renal vasodilatation, negative sodium balance, and a reduction in glomerular protein leakage. These data are consistent with a renoprotective potential of renin inhibition.

  • The chronic kidney disease “epidemy” in: Orvosi Hetilap Volume Issue 2 ()
  • Cataract szürkehályog kezelésére a cukorbetegség

When administered systemically, renin inhibitors reduce blood pressure in healthy volunteers and hypertensive patients more or less similarly to ACEi [ 4—7 ].

The renal haemodynamic actions of renin inhibitors so far have been consistent with a renoprotective potential.

renal disease secondary to diabetes

Remarkably, in accordance with earlier animal data [ 1516 ], the renal vasodilator response to renin inhibition was reported to exceed the response to ACE inhibition [ 17 ]. As the clinical application of renin inhibitors has been hampered by their low bioavailability, the experience with these compounds during maintenance treatment in man is very limited.

No data are available thus far on the renal effects of continued treatment with remikiren, or on the renal effects of renin inhibition in patients with renal function impairment and proteinuria.

renal disease secondary to diabetes

In the present study, therefore, we report on the renal and systemic effects of continued treatment for 8 days the renin inhibitor remikiren in hypertensive patients with normal renal function, as well as in patients with impaired renal function and proteinuria.

Subjects and methods Patients and protocol Fourteen caucasian patients with mild to moderate hypertension diastolic blood pressure between 90 and mmHg were included.

DOI: This study aimed to determine if there are age-related differences in chronic kidney disease-mineral and bone disorder CKD-MBD characteristics, including treatment practice in Hungarian dialysis patients.

No other clinical relevant target organ damage was allowed. All subjects gave their informed consent and the study was approved by the Ethical Committee of the Hospital. Median age of the patients was 53 years range 32— The median body mass index at baseline was Histological diagnoses were glomerulosclerosis 3 ; membranous glomerulopathy 2and IgA nephropathy 1. Systolic blood pressure at entry was ±2 mmHg range — and diastolic blood pressure was ±2 mmHg range 90— ; these values were similar for the essential hypertensives and the renal patients.

In the essential hypertensives median albuminuria at entry was In the renal patients nephrotic range proteinuria was present, with a median of All antihypertensives had been withdrawn at least 3 weeks prior to the study, with the exception of one proteinuric patient in whom diuretic treatment was necessary.

The dose of the diuretic was kept constant throughout the protocol. This patient was excluded from the analysis of electrolyte balance. During hospitalization they received a diet containing 50 mmol sodium, mmol potassium, 60 g protein, and ml fluids daily. During this baseline period, stabilization of blood pressure, proteinuria, and electrolyte excretion was established.

Subsequently, remikiren treatment mg orally o. Blood pressure was measured daily between 11 and 12 a. Renal haemodynamic measurements were performed pretreatment cukorbetegség és kurkuma on the fifth day of remikiren treatment. On the first and the last treatment day timed blood samples were drawn for measurement of plasma renin activity PRAimmunoreactive renin irRand angII.

For each hour the mean value was calculated. Urinary protein was measured by the pyrogallol red—molybdate method. This method has a coefficient of variation of During analysis plasma was first separated from plasma proteins by ethanol extraction.

Clinical trials

The lower limit of detection is 3. Circulating levels of remikiren were determined by the radioinhibitor assay of Cumin et al. Glomerular filtration 1rate GFR and effective renal plasma flow ERPF were measured as the renal clearances of constantly infused [I]iothalamate and [I]hippuran respectively. Correction for urine collection errors was applied as described previously [ 19 ].

Values are normalized for body surface area.